ArticleBreast cancer research : BCR2025
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrastuzumab, pertuzumab, and docetaxel (THP) have represented the standard first-line treatment for HER2-positive metastatic breast cancer (MBC) for over a decade, following the pivotal CLEOPATRA trial. However, interim results from the DESTINY-Breast09 trial suggest that trastuzumab deruxtecan (T-DXd) may soon replace THP as the new first-line standard. Recent developments in treatment have raised new questions about how best to match therapy intensity with individual patient profiles. FDG PET/CT, routinely used for metabolic imaging, might help by identifying patients with differing prognoses based on baseline tumor activity. We investigated the prognostic relevance of baseline FDG PET/CT and its association with treatment outcomes in HER2-positive MBC patients receiving first-line THP.
methodsWe retrospectively analyzed 194 patients with HER2-positive MBC who underwent baseline FDG PET/CT within 12 months before initiating THP therapy (2017–2024). SUVmax was recorded, and optimal cut-off values for progression-free survival (PFS) was determined by ROC analysis. Cox regression and logistic regression were used to identify independent predictors of PFS, OS, and long-term response (PFS ≥ 35 months).
resultsMedian PFS was 29.1 months; 2-year PFS was 60.3%. SUVmax > 9.6 was associated with significantly shorter PFS (18.9 vs. 43.9 months; p = 0.002) and remained independently prognostic in multivariate analysis (HR 1.98; p = 0.001). Median OS was 85.0 months. Among 162 evaluable patients, 35% were classified as long responders. ER positivity (OR 4.82), oligometastatic disease (OR 2.60), and low SUVmax (≤ 9.6; OR 2.78) were independent predictors of durable benefit.
conclusionsBaseline SUVmax derived from FDG PET/CT is an independent predictor of PFS in HER2-positive MBC treated with first-line THP. Integration of metabolic imaging biomarkers with clinical and molecular factors may support more personalized treatment approaches in this evolving therapeutic setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.